Researchers from UPMC Hillman Cancer Center and colleagues published their results from the CAMILLA trial showing that combining cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer is a promising treatment, potentially expanding treatment options for patients with microsatellite stable…